Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
SAN DIEGO, May 22, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced that the late-breaking abstracts accepted for presentation at the Endocrine Society’s annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date. The abstract for the Phase 2, open-label study of atumelnant* (CRN04894), in Congenital Adrenal Hyperplasia contained summary data for four subjects at the time of submission. We plan to present additional data from a total of six subjects in cohort 1 and additional subjects in cohort 2 at ENDO 2024. The more fulsome data set will be shared within the poster presentations scheduled to be presented on June 3, 2024, at 12:00 – 1:30 pm ET during the Late-Breaking Poster Presentation session. *Proposed international nonproprietar
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Acromegaly Major Markets: Drugs, Epidemiology, Trends, Opportunities, Forecast (2024-2034) Featuring Novartis, Pfizer, Crinetics Pharmaceuticals, Camurus [Yahoo! Finance]Yahoo! Finance
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $80.00 price target on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its price target raised by analysts at Oppenheimer Holdings Inc. from $55.00 to $74.00. They now have an "outperform" rating on the stock.MarketBeat
- Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $60.00 price target on the stock.MarketBeat
CRNX
Earnings
- 5/9/24 - Miss
CRNX
Sec Filings
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- 6/11/24 - Form 4
- CRNX's page on the SEC website